𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice

✍ Scribed by Ion Gresser; Chantal Maury; Micheal Tovey

Book ID
113146085
Publisher
Elsevier Science
Year
1978
Weight
228 KB
Volume
14
Category
Article
ISSN
0014-2964

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interferon and murine leukemia. VII. The
Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in akr mice
✍ Ion Gresser; Chantal Maury; Michael Tovey πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 French βš– 388 KB

## Abstract Daily administration of potent mouse interferon preparations, begun after clinical diagnosis of lymphoma in AKR mice, increased average survival by approximately 100%. Interferon treatment delayed the evolution of the lymphoma but regression of tumor was not observed. The therapeutic ef

Lymphoma development of simultaneously c
Lymphoma development of simultaneously combined exposure to two radiofrequency signals in AKR/J mice
✍ Hae-June Lee; Yeung Bae Jin; Jae-Seon Lee; Soo Yong Choi; Tae-Hong Kim; Jeong-Ki πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 287 KB

## Abstract There are public concerns regarding possible carcinogenic or cancer‐promoting effects of radiofrequency electromagnetic fields (RF‐EMFs) because of the extensive use of wireless mobile phones and other telecommunication devices in daily life. However, so far it is unclear if non‐thermal

Combination trial of subcutaneous interf
Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma
✍ Howard Ozer; James R. Anderson; Bruce A. Peterson; Daniel R. Budman; Edward S. H πŸ“‚ Article πŸ“… 1987 πŸ› Springer US 🌐 English βš– 482 KB

Patients with follicular non-Hodgkin's lymphoma (NHL) respond well to chemotherapy but frequently relapse and progress with conversion to more aggressive histology lymphomas. In a prior Cancer and Leukemia Group B (CALGB) trial, oral cyclophosphamide, given as a single agent, was found to be equival